Strides Arcolab announced that it has received approval from the United States Food & Drug Administration (USFDA) for Tacrolimus Capsules USO, 0.5 mg, 1 mg and 5 mg.

According to IMS data as on September 2013, the US market for generic Tacrolimus is approximately USD 676 million. The product will be manufactured at the company's oral dosage facility at Bangalore and marketed directly by Strides in the US market.

Shares of the company gained Rs 7.85, or 1.16%, to trade at Rs 682.05. The total volume of shares traded was 70,764 at the BSE (10.16 a.m., Wednesday).